GeneDx Holdings Corporation News - WGS | Aktien NASDAQ

Ihr Hub für Echtzeit-Streaming-Zitate, Ideen und Live-Diskussionen

GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that, effective as of March 15...

Fast Company Recognizes GeneDx as One of the World's Most Innovative Companies

GeneDx recognized for its innovative approach to accelerating genetic diagnosis and transforming the future of healthcare by ending the...

Landmark Seqfirst-neo Study Showcases the Significant Impact of Genomic Testing in the NICU, Revealing Gaps in Current Protocols

Findings published in the American Journal of Human Genetics reveals widespread use of rapid genome sequencing (rGS) demonstrates that more...

GeneDx Reports Fourth Quarter and Full Year 2024 Financial Results and Issues Guidance for Full Year 2025

Grew fourth quarter 2024 revenues1 to $95.3 million Expanded fourth quarter 2024 adjusted gross margins1,2 to 70% Generated fourth quarter 2024...

GeneDx Announces ultraRapid Whole Genome Sequencing, Delivering Actionable Results in as soon as 48 Hours to Inform Care for Critically Ill NICU and PICU Patients

ultraRapid testing addresses the underutilization of testing in the NICU and can lead to more than $15K in healthcare savings per child GeneDx...

GeneDx to Participate in 45th Annual TD Cowen Health Care Conference

GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that company management will...

GeneDx Integrates with Epic, Enabling Broad Adoption of Genome and Exome Sequencing for Health Systems to Inform Patient Diagnosis and Accelerate Treatment

UNC Health to Become the First Health System to Collaborate with GeneDx Through Aura, Epic’s Specialty Diagnostic Suite GeneDx (Nasdaq: WGS), a...

GeneDx to Report Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 18, 2025

GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, announced it will release financial results for...

GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that, effective as...

GeneDx Announces Preliminary 2024 Financial Results

Expects to exceed guidance with full year 2024 revenues1 of at least $299 million Expects fourth quarter 2024 revenues1 of at least $92 million...

GeneDx Introduces New Telehealth Pathway to Expand Access to Exome Testing for Parents Seeking Answers

GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced a new way to provide genetic...

GeneDx Continues its Leadership in Genomics Research, Refining Gene-Disease Relationships and Impacting Results of >22,000 Patients

Contributed nearly one quarter of all submissions to GeneMatcher and collaborated on more than 85 peer reviewed publications in 2024 GeneDx...

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

GeneDx Holdings Corporation (WGS)

Ihr Hub für Echtzeit-Streaming-Zitate, Ideen und Live-Diskussionen

WGS Nachrichten

GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fast Company Recognizes GeneDx as One of the World's Most Innovative Companies

Landmark Seqfirst-neo Study Showcases the Significant Impact of Genomic Testing in the NICU, Revealing Gaps in Current Protocols

GeneDx Reports Fourth Quarter and Full Year 2024 Financial Results and Issues Guidance for Full Year 2025

GeneDx Announces ultraRapid Whole Genome Sequencing, Delivering Actionable Results in as soon as 48 Hours to Inform Care for Critically Ill NICU and PICU Patients

GeneDx to Participate in 45th Annual TD Cowen Health Care Conference

GeneDx Integrates with Epic, Enabling Broad Adoption of Genome and Exome Sequencing for Health Systems to Inform Patient Diagnosis and Accelerate Treatment

GeneDx to Report Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 18, 2025

GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GeneDx Announces Preliminary 2024 Financial Results

GeneDx Introduces New Telehealth Pathway to Expand Access to Exome Testing for Parents Seeking Answers

GeneDx Continues its Leadership in Genomics Research, Refining Gene-Disease Relationships and Impacting Results of >22,000 Patients

GeneDx Strengthens Executive Leadership Team with Bryan Dechairo Named Chief Operating Officer

GeneDx to Present at the 43rd Annual J.P. Morgan Healthcare Conference

GeneDx to Expand Access to Exome Testing for Pediatric Epilepsy Patients with New Partners

WGS Finanzen

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

GeneDx Holdings Corporation (WGS) News

GeneDx Holdings Corporation (WGS)

Ihr Hub für Echtzeit-Streaming-Zitate, Ideen und Live-Diskussionen

WGS Nachrichten

GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fast Company Recognizes GeneDx as One of the World's Most Innovative Companies

Landmark Seqfirst-neo Study Showcases the Significant Impact of Genomic Testing in the NICU, Revealing Gaps in Current Protocols

GeneDx Reports Fourth Quarter and Full Year 2024 Financial Results and Issues Guidance for Full Year 2025

GeneDx Announces ultraRapid Whole Genome Sequencing, Delivering Actionable Results in as soon as 48 Hours to Inform Care for Critically Ill NICU and PICU Patients

GeneDx to Participate in 45th Annual TD Cowen Health Care Conference

GeneDx Integrates with Epic, Enabling Broad Adoption of Genome and Exome Sequencing for Health Systems to Inform Patient Diagnosis and Accelerate Treatment

GeneDx to Report Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 18, 2025

GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GeneDx Announces Preliminary 2024 Financial Results

GeneDx Introduces New Telehealth Pathway to Expand Access to Exome Testing for Parents Seeking Answers

GeneDx Continues its Leadership in Genomics Research, Refining Gene-Disease Relationships and Impacting Results of >22,000 Patients

GeneDx Strengthens Executive Leadership Team with Bryan Dechairo Named Chief Operating Officer

GeneDx to Present at the 43rd Annual J.P. Morgan Healthcare Conference

GeneDx to Expand Access to Exome Testing for Pediatric Epilepsy Patients with New Partners

WGS Finanzen

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Werbung entfernen